Multi-scale classification decodes the complexity of the human E3 ligome
- PMID: 41449181
- PMCID: PMC12741051
- DOI: 10.1038/s41467-025-67450-9
Multi-scale classification decodes the complexity of the human E3 ligome
Abstract
E3 ubiquitin ligases are vital enzymes that define the ubiquitin code in cells. Beyond promoting protein degradation to maintain cellular health, they also mediate non-degradative processes like DNA repair, signaling, and immunity. Despite their therapeutic potential, a comprehensive framework for understanding the relationships among diverse E3 ligases is lacking. Here, we classify the "human E3 ligome"-an extensive set of catalytic human E3s-by integrating multi-layered data, including protein sequences, domain architectures, 3D structures, functions, and expression patterns. Our classification is based on a metric-learning paradigm and uses a weakly supervised hierarchical framework to capture authentic relationships across E3 families and subfamilies. It extends the categorization of E3s into RING, HECT, and RBR classes, including non-canonical mechanisms, successfully explains their functional segregation, distinguishes between multi-subunit complexes and standalone enzymes, and maps E3s to substrates and potential drug interactions. Our analysis provides a global view of E3 biology, opening strategies for drugging E3-substrate networks, including drug repurposing and designing specific E3 handles.
© 2025. The Author(s).
Conflict of interest statement
Competing interests: R.M.B., M.K., K.H., and I.D. are head scientists at the Frankfurt Competence Center for Emerging Therapeutics (FCET), Goethe Center for (high) technology (Go4Tec), Goethe University, Frankfurt am Main, Germany. The remaining authors declare no competing interests. This manuscript reflects the views of the authors, and neither IMI nor the European Union, EFPIA, nor any associated partners are liable for any use that may be made of the information contained herein. I.D. is a founder/shareholder of Vivlion GmbH and a member of its scientific advisory board. I.D. is also a member of the scientific advisory board of the Boehringer Ingelheim Foundation, the expert committee (for international research leader grants) of the Novo Nordisk Foundation, and the advisory board of Cell and Molecular Cell. I.D. was a founder and consultant of Caraway Therapeutics Inc. M.K. is a co-founder, shareholder, and chief officer of Vivlion GmbH.
Figures
References
MeSH terms
Substances
Grants and funding
- PROXIDRUGs project, InnoDATA-1.0 ID 03ZU1109KA and InnoDATA-2.0 ID 03ZU2109JA/Bundesministerium für Bildung und Forschung (Federal Ministry of Education and Research)
- Project-ID 259130777-SFB1177/Deutsche Forschungsgemeinschaft (German Research Foundation)
- Project-ID 259130777-SFB1177/Deutsche Forschungsgemeinschaft (German Research Foundation)
LinkOut - more resources
Full Text Sources
